Small Cap Network Blog

Although we’re not covering the company anymore, we still wanted to follow up with a quick note here for any of our readers who are still following the story…

You may remember from a few weeks ago our blog entry regarding Multicell Technologies’ (OTCBB: MCET) research on cancer treatment via immune system modulation. In lay-person’s terms (which is us), the distinguishing characteristic of this drug was simply that it induced a patient’s own immune system to destroy a tumor. Lab testing showed that morbidity and mortality was prevented in 60% of the samples. 

Well, we got the second wave today. Not only is the experimental drug (a combination of a drug called MCT-465 and another patented antigen-presenting therapy) effective at killing cancerous tumors, it’s also been shown effective at preventing recurrent cancer. In a press release issued this morning, Multicell announced that when they re-introduced a cancer into mice that had previously survived a cancer because of MCT-465, all of those mice were protected against the development of secondary cancers. The control group - the comparison - all developed tumors. In other words, in early lab testing, MCT-465 has been shown to beat cancer, and keep it beaten.

In our opinion, this is huge. Most cancer survivors are likely to develop cancer again. Now with at least promising lab tests, Multicell may be on track to slow down recurrent cancer in humans. There’s a lot more work and time involved before we get to that stage, but the potential of such a development could be huge.

Just thought you should know.

Here’s a link to the press release, which describes the process in more detail.